Personalized cancer therapies: RNA treatments designed for one patient at a time

Our N-Force RNA Platform delivers personalized cancer treatments that are fast, viable at a fraction of current cost, and decentralized. It enables a deployable solution close to the point of need: regional hubs, hospitals, or on-site manufacturing.

Stylized cancer cell targeted in a microscopic field — personalized RNA therapies

At a glance

Quantoom's vision

≤ 1 week

Biopsy-to-injection turnaround time

At a fraction

of current cost / patient

Decentralized

Deployable at or near point-of-care

Fast, low cost and decentralized

We power the paradigm shift: a fast, flexible, end-to-end workflow that turns a biopsy into a personalized RNA treatment.

While today's biopsy-to-treatment cycle runs several weeks (4 weeks), our ambition is to go one step further:

Obtaining a needle to needle cycle in less than a week at a fraction of today's cost, deployable at or near the point of care.

Because for a cancer patient, time, access and cost are the treatment.

Ntensify® micro — compact RNA production for a single-patient batch at or near the point of care
R&D programs

Personalized cancer treatments

Quantoom is active on multiple R&D programs in this field.

To learn more, please contact us.

Personalized mRNA vaccine targeting a tumor cell — R&D programs in personalized cancer treatments
How we work with partners

Manufactured for you, or produced in your facility

Hospitals, research centers and biotechs can start with Quantoom manufacturing, then take design and production in-house when they are ready — on the same N-Force process.

Manufacturing with Quantoom

Quantoom designs and manufactures personalized cancer RNA treatments for hospitals, oncology centers and biotechs.

Production at your site

A technology transfer gives you Quantoom's end-to-end workflow. You then design and manufacture at your facility, under your own control. Ncode, Ntensify® and Ncapsulate® stay in the process so every patient-specific batch follows the same path.

Research partnership

Quantoom collaborates with a US-based top cancer center

Personalized cancer therapeutics moves further when the right science meets the right clinic. The collaboration covers mRNA formulation technology — a research license and supply agreement for treatments designed around a single patient.

Press Release

Quantoom Biosciences Signs Research License and Supply Agreement with Leading Global Cancer Center for mRNA Formulation Technology in Personalized Cancer Therapeutics

Read the announcement

For any questions or requests

Please contact us and we will respond quickly!

Book a callContact us